NVO
Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 106.47$. Average daily volumn in 3 months 1.67M. Market cap 226.77B
Stock symbol : NVO. Exchange : NYSE. Currency : USD Lastest price : 100.14$. Total volume : 1.13M. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Novo Nordisk A/S (NVO)
Last Price
100.14$Change
0.78Volume
1.13M
| Previous Close | 99.36 |
| Open | 100.40 |
| Day Range | 99.61-100.92 |
| Bid | 100.36 x 1.4k |
| Ask | 100.40 x 1.8k |
| Volume | 1.13M |
| Average Volume | 1.67M |
| Market Cap | 226.77B |
| Beta | 0.29 |
| 52 Week Range | 91.51-122.16 |
| Trailing P/E | 34.29 |
| Foward P/E | 27.21 |
| Dividend (Yield %) | 1.63% |
| Ex-Dividend Date | 2022-08-12 |
Financial Details
Organization
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormon... e replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Market Cap:
226.77BRevenue:
140.8BTotal Assets:
194.51BTotal Cash:
10.72B
News about "Novo Nordisk A/S"
Novo Nordisk A/S – Share repurchase programme
Source from : Yahoo - 3 days ago
On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»
Novo Nordisk pays $70M for a Phase 1-ready cardiometabolic disorder drug
Source from : MedCity News - 9 hours ago
Novo Nordisk is acquiring global rights to a Ventus Therapeutics drug candidate with potential applications in cardiometabolic disorders such as NASH and chronic kidney disease. The small molecule ...See details»
Montreal’s Ventus Therapeutics strikes US$700-million-plus deal with pharma giant Novo Nordisk
Source from : The Globe and Mail - 17 hours ago
Montreal biotechnology company Ventus Therapeutics Inc. has struck a development and licensing deal with pharma giant Novo Nordisk A/S NVO-N that could be worth more than US$700-million ($960-million) ...See details»
Allworth Financial LP Acquires 138 Shares of Novo Nordisk A/S (NYSE:NVO)
Source from : Defense World - 1 days ago
Allworth Financial LP grew its stake in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 34.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange ...See details»
HB Wealth Management LLC Raises Position in Novo Nordisk A/S (NYSE:NVO)
Source from : Defense World - 2 days ago
HB Wealth Management LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 22.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional ...See details»
Ventus sells its lead drug candidate to Novo Nordisk
Source from : BioPharma Dive - 13 hours ago
The biotechnology startup will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordisk’s bet on inflammasome treatments.See details»
Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program
Source from : YAHOO!Finance - 14 hours ago
Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a ...See details»
Ventus Therapeutics cuts $70m deal with Danish drug giant Novo Nordisk
Source from : The Boston Globe on MSN - 15 hours ago
The local company is working on drugs to treat conditions such as nonalcoholic fatty liver disease and chronic kidney disease.See details»
Ominous Death Cross Forms On Novo Nordisk's Chart
Source from : Benzinga.com on MSN - 3 days ago
If history is any guide, there may be trouble ahead for shares of Novo Nordisk (NYSE:NVO). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.See details»
Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’
Source from : BioPharma Dive - 8 days ago
The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences.See details»
Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research
Source from : labiotech - 7 days ago
The Novo Nordisk Foundation has awarded a $200M grant for the first full-scale quantum computer to develop new medicines.See details»
Prothena: Paying A Premium To Cover All The Alzheimer's Bases
Source from : Seeking Alpha - 8 hours ago
Prothena's share price returns are dictated by the progress of other companies further advanced in the drug development process. Read why I give PRTA a hold rating.See details»
Novo Nordisk and Octagon Therapeutics Enter Inflammatory Disease Research Collaboration
Source from : PharmTech - 1 days ago
The collaboration will use Octagon’s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise. Octagon Therapeutics, a ...See details»
Q&A: Novo Nordisk’s Keith Middleton on its latest DE&I efforts
Source from : MM&M - 7 days ago
How is Novo Nordisk differentiating what it’s doing compared to other players in the space? Middleton: The fact that we work in the therapeutic areas of the diseases that we do, it highlights a huge ...See details»